Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
28 pending office actions • 12 art units • 24 examiners • 0 of 28 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days
Novo Nordisk Inc. has 27 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 23 distinct examiners and 11 distinct art units, showing that the pending portfolio is spread across examiners while remaining within a more limited set of technical examination groups.
CHANDRA, GYAN is the busiest examiner, with 2 pending matters. That assignment represents only a small portion of the company’s pending activity, so prosecution planning should account for varied examiner practices rather than rely on one recurring examiner relationship. Art-unit tracking may provide a useful organizing layer for coordinating responses across the portfolio.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (25%) |
| §102 only | 1 (4%) |
| §112 only | 2 (7%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 4 (14%) |
| Multi-statute (no §101) | 12 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRA, GYAN | 2 | 71.3% | +27.6% |
| HELLMAN, KRISTINA M | 2 | 65.1% | +55.6% |
| ARCORIA, PAUL JOSEPH | 2 | 66.7% | +50.0% |
| BRADLEY, CHRISTINA | 2 | 62.4% | +32.7% |
| COFFA, SERGIO | 1 | 61.2% | +32.3% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 36.2% | +35.5% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +48.2% |
| GALSTER, SAMUEL LEONARD | 1 | 51.2% | +40.2% |
| KASHYAP, ESHA PRAKASH | 1 | 100.0% | +0.0% |
| ANTHOPOLOS, PETER | 1 | 57.6% | +58.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | 26d |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | — |
| 19355693 | ANTAGONISTS OF HUMAN FGF23 | BENAVIDES, JENNIFER ANN | — |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
| 18681845 | INGESTIBLE DEVICE | KASHYAP, ESHA PRAKASH | — |
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | ANTHOPOLOS, PETER | — |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | BRADLEY, CHRISTINA | — |
| 17782313 | FIXED DOSE INJECTION DEVICE | FARRAR, LAUREN PENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19463848 | SEMAGLUTIDE IN MEDICAL THERAPY | COFFA, SERGIO | — |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | — |
| 19404431 | TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF | HELLMAN, KRISTINA M | — |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 19355693 | ANTAGONISTS OF HUMAN FGF23 | BENAVIDES, JENNIFER ANN | — |
| 18839945 | METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE | ARCORIA, PAUL JOSEPH | — |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 3783 | 7 |
| 1654 | 4 |
| 1658 | 3 |
| 1674 | 3 |
| 1621 | 2 |
| 1693 | 2 |
| 1626 | 2 |
| 1675 | 1 |
| 1641 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19463848 | SEMAGLUTIDE IN MEDICAL THERAPY | COFFA, SERGIO | 1658 | DP | Final Rejection | — | Pending | Jan 29, 2026 |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | CHANDRA, GYAN | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 10, 2025 |
| 19404431 | TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF | HELLMAN, KRISTINA M | 1654 | §112 | Non-Final OA | — | Pending | Dec 01, 2025 |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112DP | Non-Final OA | — | Pending | Nov 04, 2025 |
| 19355693 | ANTAGONISTS OF HUMAN FGF23 | BENAVIDES, JENNIFER ANN | 1675 | §102§112 | Non-Final OA | — | Pending | Oct 10, 2025 |
| 18839945 | METHODS FOR TREATING SUBJECTS WITH ABDOMINAL OBESITY HYPERTRIGLYCERIDEMIA AND/OR IMPAIRED GLUCOSE | ARCORIA, PAUL JOSEPH | 1621 | §103 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18837928 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18673424 | Combination Therapy for Treatment of Liver Disease | BRADLEY, CHRISTINA | 1654 | §103 | Non-Final OA | — | Pending | May 24, 2024 |
| 18681845 | INGESTIBLE DEVICE | KASHYAP, ESHA PRAKASH | 3783 | §102§103 | Final Rejection | — | Pending | Feb 06, 2024 |
| 18426412 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | CHANDRA, GYAN | 1674 | §102§103DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18578485 | SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A | ANTHOPOLOS, PETER | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Final Rejection | 5d overdue | Pending | Sep 06, 2023 |
| 18280092 | RNAI CONJUGATES AND USES THEREOF | KONOPKA, CATHERINE ANNE | 1635 | §103DP | Final Rejection | — | Pending | Sep 01, 2023 |
| 18271985 | A TORSION SPRING DRIVEN FIXED DOSE INJECTION DEVICE | MEDWAY, SCOTT J | 3783 | §102 | Final Rejection | — | Pending | Jul 12, 2023 |
| 18252056 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | BRADLEY, CHRISTINA | 1654 | §103§112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18020386 | INGESTIBLE DRUG DELIVERY DEVICE | GONZALEZ, LEI NMN | 3783 | §103 | Non-Final OA | 26d | Pending | Feb 08, 2023 |
| 18019404 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | CHO, DAVID H | 1693 | §103Other | Final Rejection | 53d | Pending | Feb 02, 2023 |
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | 1674 | §103§112 | Non-Final OA | 26d | Pending | Jan 10, 2023 |
| 17913292 | Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors | SAEED, KAMAL A | 1626 | §112 | Final Rejection | — | Pending | Sep 21, 2022 |
| 17800747 | GLP-1 COMPOSITIONS AND USES THEREOF | ATKINSON, JOSHUA ALEXANDER | 1612 | DP | Final Rejection | 31d overdue | Pending | Aug 18, 2022 |
| 17782313 | FIXED DOSE INJECTION DEVICE | FARRAR, LAUREN PENG | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17782003 | AN INJECTION DEVICE FOR DELIVERING A LIQUID DRUG | NORTH, ISABELLA SARAH HYO SO | 3783 | §102§103 | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17638483 | PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES | HELLMAN, KRISTINA M | 1654 | §102§112Other | Final Rejection | — | Pending | Feb 25, 2022 |
| 17616283 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | — | Pending | Dec 03, 2021 |
| 17614077 | DUAL CHAMBER DRUG RESERVOIR AND STOPPER THEREFOR | RITCHIE, HADEN MATTHEW | 3783 | §102§103 | Final Rejection | — | Pending | Nov 24, 2021 |
| 17403357 | COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF | REYNOLDS, FRED H | 1658 | §103§112Other | Non-Final OA | — | Pending | Aug 16, 2021 |
| 17286639 | ZERO-POINT ADJUSTMENT OF PREFILLED DRUG DELIVERY DEVICE | ZAMORY, JUSTIN L | 3783 | §103 | Final Rejection | — | Pending | Apr 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovo Nordisk Inc. has 28 pending office actions as of November 2026, spread across 12 art units and 24 examiners.
Gyan Chandra has the most, with 2 of Novo Nordisk Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.